Ahmadi-Asrbadr Yadollah, Hemmati-Ghavshough Mahdi, Khanzadeh Navid, Ansari Fereshteh, Mohammad-Rahimi Mohsen
Department of Urology, Tabriz Medical University Tabriz, Iran.
Medical Faculty, Tabriz Medical University Tabriz, Iran.
Am J Clin Exp Urol. 2022 Aug 15;10(4):258-265. eCollection 2022.
Considering that the use of aromatase inhibitors in the treatment of infertile men is a new approach and obesity in men is one of the factors affecting infertility, we decided to compare the effect of combined therapy of Human chorionic gonadotropin (HCG) and Letrozole and either of the two methods alone on the spermogram parameters in obese men with idiopathic infertility.
This clinical trial study was performed with the participation of 15 infertile and obese men from 2018 to 2019 in Tabriz (infertility clinics); Patients were randomly divided into three groups; The first group received treatment with Letrozole 2.5 mg daily alone, the second group received treatment with HCG ampoules at a dose of 5000 units twice a week, and the third group received combination therapy with HCG ampoules at a dose of 5000 units twice a week and letrozole tablets at a dose of 2.5 mg daily; The results of testosterone and sperm tests before and after the intervention were evaluated by t-test and linear regression tests in SPSS21 software. A -value less than 0.05 was considered significant.
There was no statistically significant difference between semen indices and hormones studied before the intervention (P < 0.05), while after the intervention there were statistically significant differences between all variables compared to those before the intervention (P < 0.05); Also, the rate of change in the third group was much more favorable than the other two groups.
The combination of HCG ampules with letrozole tablets compared to the use of these drugs alone improved sperm count, sperm motility, and sperm morphology.
鉴于使用芳香化酶抑制剂治疗不育男性是一种新方法,且男性肥胖是影响不育的因素之一,我们决定比较人绒毛膜促性腺激素(HCG)与来曲唑联合治疗以及单独使用这两种方法中的任何一种对患有特发性不育的肥胖男性精液参数的影响。
本临床试验研究于2018年至2019年在大不里士(不育诊所)进行,有15名不育且肥胖的男性参与;患者被随机分为三组;第一组仅接受每日2.5毫克来曲唑治疗,第二组接受每周两次、剂量为5000单位的HCG安瓿治疗,第三组接受每周两次、剂量为5000单位的HCG安瓿与每日2.5毫克来曲唑片的联合治疗;干预前后的睾酮和精液检测结果在SPSS21软件中通过t检验和线性回归检验进行评估。P值小于0.05被认为具有统计学意义。
干预前研究的精液指标和激素之间无统计学显著差异(P < 0.05),而干预后与干预前相比,所有变量之间均有统计学显著差异(P < 0.05);此外,第三组的变化率比其他两组更有利。
与单独使用这些药物相比,HCG安瓿与来曲唑片联合使用可改善精子数量、精子活力和精子形态。